In Ewing sarcoma, a recent IHC study has reported that 22 out of 26 (85%) pre-treatment tumors were positive for HLA-E expression on tumor cells, infiltrating macrophages, or both; however, HLA-E expression on tumor cells did not impair the preclinical activity of GD2-specific chimeric antigen receptor (CAR) T cells (81). This evidence concerns the gene HLA-E and Ewing sarcoma.